Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review

T Fiolet, Y Kherabi, CJ MacDonald, J Ghosn… - Clinical Microbiology …, 2022‏ - Elsevier
Background Vaccines are critical cost-effective tools to control the coronavirus disease 2019
(COVID-19) pandemic. However, the emergence of variants of the severe acute respiratory …

SARS-CoV-2 variants, vaccines, and host immunity

P Mistry, F Barmania, J Mellet, K Peta… - Frontiers in …, 2022‏ - frontiersin.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new beta coronavirus
that emerged at the end of 2019 in the Hubei province of China. SARS-CoV-2 causes …

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

D Planas, N Saunders, P Maes, F Guivel-Benhassine… - Nature, 2022‏ - nature.com
Abstract The SARS-CoV-2 Omicron variant was first identified in November 2021 in
Botswana and South Africa,–. It has since spread to many countries and is expected to …

Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa

JRC Pulliam, C van Schalkwyk, N Govender… - Science, 2022‏ - science.org
We provide two methods for monitoring reinfection trends in routine surveillance data to
identify signatures of changes in reinfection risk and apply these approaches to data from …

Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron

JM Carreño, H Alshammary, J Tcheou, G Singh… - Nature, 2022‏ - nature.com
Abstract The Omicron (B. 1.1. 529) variant of severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) was initially identified in November 2021 in South Africa and Botswana, as …

Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study

P Naaber, L Tserel, K Kangro, E Sepp… - The Lancet Regional …, 2021‏ - thelancet.com
ABSTRACT Background SARS-CoV-2 mRNA vaccines have proven high efficacy, however,
limited data exists on the duration of immune responses and their relation to age and side …

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

D Planas, D Veyer, A Baidaliuk, I Staropoli… - Nature, 2021‏ - nature.com
Abstract The SARS-CoV-2 B. 1.617 lineage was identified in October 2020 in India,,,–. Since
then, it has become dominant in some regions of India and in the UK, and has spread to …

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection

Z Wang, F Muecksch, D Schaefer-Babajew, S Finkin… - Nature, 2021‏ - nature.com
More than one year after its inception, the coronavirus disease 2019 (COVID-19) pandemic
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains difficult …

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants

A Pegu, SE O'Connell, SD Schmidt, S O'Dell… - Science, 2021‏ - science.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish
vaccine-induced protective immune responses, particularly as antibody titers wane over …

[HTML][HTML] SARS-CoV-2-infection-and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase

K Srivastava, JM Carreño, C Gleason, B Monahan… - Immunity, 2024‏ - cell.com
It is thought that mRNA-based vaccine-induced immunity to severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) wanes quickly, based mostly on short-term studies …